Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | SLC8A1 | P32418 | 4/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.40 |
| ▸ | NQO2 | P16083 | 3/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.39 |
| ▸ | RBP4 | P02753 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19230992 | 0.89 | ESR2 (0.44) | NOTUMSLC8A1RBP4CFTR | |
| SCHEMBL19230577 | 0.87 | KDM4E (0.44) | SLC8A1 | |
| SCHEMBL19230991 | 0.85 | SLC8A1 (0.43) | SLC8A1 | |
| SCHEMBL19230614 | 0.81 | ESR1 (0.50) | SLC8A1 | |
| SCHEMBL19230370 | 0.79 | SLC8A1 (0.37) | NOTUMSLC8A1RBP4 | |
| SCHEMBL19230784 | 0.79 | SLC8A1 (0.36) | SLC8A1 | |
| SCHEMBL19230375 | 0.77 | ESR2 (0.46) | SLC8A1 | |
| SCHEMBL19230778 | 0.77 | NR1H4 (0.59) | — | |
| SCHEMBL19230993 | 0.76 | ESR1 (0.47) | SLC8A1 | |
| SCHEMBL19230789 | 0.76 | ESR1 (0.39) | SLC8A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108602811-B | FXR receptor agonists | 轩竹生物科技有限公司 | 2021-11-16 | — | — | CN | disclosed |
| WO-2017133521-A1 | FXR RECEPTOR AGONIST | 山东轩竹医药科技有限公司 | 2017-08-10 | — | — | WO | disclosed |
| US-20150307452-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307452-A1 | NOVEL PYRIDINE DERIVATIVES | NDUFS6, NDUFS3, NDUFV2 | NOTUM 3925/4885SLC8A1 2347/4885EPHX2 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.